Assessment of the tissue factor pathway inhibitor (TFPI-rs7586970 variant) polymorphism as a risk factor in myocardial infarction patients

Abstract

Context The tissue factor pathway inhibitor (TFPI), a Kunitz-type serine protease inhibitor, inhibits the extrinsic pathway of pathways, and might significantly contribute to the pathogenesis of coronary artery diseases. Aim To assess the TFPI-rs7586970 genetic variant as a risk factor in patients with myocardial infarction (MI). Settings and design A descriptive case–control study in the Premises of the Department of Clinical Pathology and Cardiology in Suez Canal University Hospitals included 156 individuals; 78 MI patients and 78 individuals as a control group. Methods and material An interview questionnaire, clinical and laboratory assessment, and molecular genotyping of the TFPI-rs7586970 genetic variant were done using real-time PCR Eva-Green-based high-resolution melting curve (HRM) analysis. Informed consent was taken from all the participants and the study protocol was approved by the Ethics Committee, Faculty of Medicine, Suez Canal University. Statistical analysis used For statistical analysis, t-test, Mann-Whitney U test, chi-squared-test (χ2), one-way ANOVA (analysis of variance), Kruskal-Wallis test, and binary logistic regression model were used. Results The MI group recorded 26 allele copies of the TFPI-rs7586970 genetic variant whereas the control group recorded six copies. The binary logistic regression model for MI occurrence showed that the TFPI-rs7586970 genetic variant polymorphism is a significant predictor for the development of MI. Conclusions TFPI-rs7586970 genetic variant polymorphism is a significant risk factor for the development of MI.